JP2025512121A5 - - Google Patents

Info

Publication number
JP2025512121A5
JP2025512121A5 JP2025503026A JP2025503026A JP2025512121A5 JP 2025512121 A5 JP2025512121 A5 JP 2025512121A5 JP 2025503026 A JP2025503026 A JP 2025503026A JP 2025503026 A JP2025503026 A JP 2025503026A JP 2025512121 A5 JP2025512121 A5 JP 2025512121A5
Authority
JP
Japan
Prior art keywords
seq
ang
vegf
sequence
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025503026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512121A (ja
Filing date
Publication date
Priority claimed from CN202210356939.6A external-priority patent/CN116925234B/zh
Application filed filed Critical
Publication of JP2025512121A publication Critical patent/JP2025512121A/ja
Publication of JP2025512121A5 publication Critical patent/JP2025512121A5/ja
Pending legal-status Critical Current

Links

JP2025503026A 2022-04-02 2023-03-31 抗ＶＥＧＦ－Ａおよび抗Ａｎｇ－２二重特異性抗体をコードするＡＡＶベクター Pending JP2025512121A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210356939.6 2022-04-02
CN202210356939.6A CN116925234B (zh) 2022-04-02 2022-04-02 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
PCT/CN2023/085610 WO2023186131A1 (zh) 2022-04-02 2023-03-31 一种编码抗vegf-a和ang-2双特异性抗体的aav载体

Publications (2)

Publication Number Publication Date
JP2025512121A JP2025512121A (ja) 2025-04-16
JP2025512121A5 true JP2025512121A5 (https=) 2026-03-13

Family

ID=88199501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025503026A Pending JP2025512121A (ja) 2022-04-02 2023-03-31 抗ＶＥＧＦ－Ａおよび抗Ａｎｇ－２二重特異性抗体をコードするＡＡＶベクター

Country Status (5)

Country Link
US (1) US20250223345A1 (https=)
EP (1) EP4506367A4 (https=)
JP (1) JP2025512121A (https=)
CN (2) CN116925234B (https=)
WO (1) WO2023186131A1 (https=)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE187494T1 (de) * 1992-12-11 1999-12-15 Dow Chemical Co Multivalente einkettige antikörper
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
ZA200705695B (en) * 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
EP1962903B1 (en) * 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
SG11201408538PA (en) * 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
KR20150063847A (ko) * 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-A/항 Ang2 이중 특이 항체
JP2017534644A (ja) * 2014-11-10 2017-11-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ａｎｇ２抗体及び使用方法
BR112017009764A2 (pt) * 2014-11-10 2018-02-20 Hoffmann La Roche anticorpos biespecíficos e métodos de uso em oftalmologia
WO2018007314A1 (en) * 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
US10836819B2 (en) * 2016-08-23 2020-11-17 Medimmune Limited Anti-VEGF-A and anti-ANG2 antibodies and uses thereof
EP3687464A4 (en) * 2017-09-27 2021-09-29 REGENXBIO Inc. TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB
MX2020003888A (es) * 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
WO2021255589A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof
WO2021255590A1 (en) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof
EP4208201A1 (en) * 2020-09-04 2023-07-12 F. Hoffmann-La Roche AG Antibody that binds to vegf-a and ang2 and methods of use
TW202227509A (zh) * 2020-09-15 2022-07-16 日商參天製藥股份有限公司 針對vegf及ang2之雙特異性結合分子
CN113185613B (zh) * 2021-04-13 2022-09-13 武汉大学 新型冠状病毒s蛋白及其亚单位疫苗
CN115772544B (zh) * 2021-09-06 2024-04-26 合肥星眸生物科技有限公司 抗vegf-a和ang-2的aav载体

Similar Documents

Publication Publication Date Title
AU2022203494B2 (en) Adeno-Associated Virus Variant Capsids And Use For Inhibiting Angiogenesis
JP6868572B2 (ja) アフィニティー精製工程を含む組換えアデノ随伴ウイルス粒子の精製
Vandenberghe et al. Tailoring the AAV vector capsid for gene therapy
JP2023531451A5 (https=)
Rabinowitz et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity
JP2024514956A5 (https=)
CN116209768A (zh) 用于通过高变区交换工程化新杂合aav衣壳的方法
US20070243526A1 (en) AAV capsid library and AAV capsid proteins
EP4004214A1 (en) Engineered nucleic acid regulatory element and methods of uses thereof
TW201704253A (zh) 殼體
JP2026508054A (ja) 治療薬の生体内分布および有効性の受容体媒介制御のための標的
US20190240328A1 (en) Novel humanized anti-ebola antibodies useful in preventing ebola infections
US20260055144A1 (en) Recombinant adeno-associated viruses and uses thereof
TW202434886A (zh) 用於偵測及評估病毒及類病毒顆粒的方法
US20250207126A1 (en) Modified muscle-specific promoters
JP2021511020A5 (https=)
JP2022531892A5 (https=)
JP2025512121A5 (https=)
US20210017542A1 (en) Aav6 variants
AU2024290842A1 (en) Engineered aav capsid proteins
WO2025128551A9 (en) Aav-based anti-ga therapy
JP2025525027A (ja) アデノ随伴ウイルスベクターならびに転移のリスク低減、処置、および予防のためのそれらの使用方法
WO2024216244A9 (en) Targeting aav capsids, methods of manufacturing and using same
WO2023077092A1 (en) Engineered nucleic acid regulatory elements and methods and uses thereof
JP2025525035A (ja) アデノ随伴ウイルスベクターならびに転移のリスク低減、処置、および予防のためのそれらの使用方法